Commercializing a Medical Product After Patent Expiry
This paper examines strategies a pharmaceutical company can employ to sustain profitability once a two-year period of market exclusivity ends and patent protection lapses. Drawing on literature in medical law and pharmaceutical strategy, the paper evaluates three principal approaches: developing a reformulated version of the original drug to qualify for a new patent, identifying new treatment indications to expand the product's commercial life, and broadening marketing and distribution efforts. Real-world examples, including Merck's Finasteride, illustrate how companies have successfully extended commercial value beyond initial patent terms. The paper concludes that a combination of continued research and strategic commercial planning is essential to long-term profitability.
- Introduction: Patents and Market Exclusivity: Patent expiry creates competitive risk for investors
- Reformulating the Drug for a New Patent: New formulations can secure fresh patent protection
- Expanding Commercial Life Through New Treatment Indications: New approved uses extend a drug's market life
- Additional Strategies for Sustaining Profitability: Marketing, new markets, and partnerships support revenue
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Clearly frames the central problem — patent expiry and the resulting competitive threat — before methodically evaluating each strategic response.
- Grounds each strategy in cited academic and professional literature, lending credibility to the analysis even in a short paper.
- Uses a concrete real-world example (Merck's Finasteride/Proscar) to illustrate the abstract strategy of seeking new treatment indications, making the argument more persuasive.
- Honestly acknowledges the limitations and risks of each strategy, demonstrating balanced critical thinking rather than one-sided advocacy.
Key academic technique demonstrated
The paper consistently applies the technique of evaluating options against criteria — specifically, cost, feasibility, and competitive risk. Each strategy is introduced, supported with a citation or example, and then tested against potential drawbacks. This cost-benefit framing is a fundamental analytical skill in business and health sciences writing.
Structure breakdown
The paper opens with a contextual introduction establishing the two-year exclusivity window as the core business problem. It then devotes one focused paragraph to each of two primary strategies (reformulation and new indications), followed by a brief concluding paragraph that gestures toward additional complementary tactics. The reference list follows APA style.
Introduction: Patents and Market Exclusivity
It is important to note, from the outset, that patents represent the most effective approach to securing a desired market after realizing the fruits of research. This is particularly the case given that the commercialization of medical research brings with it a high level of risk for the key stakeholders involved in the entire research process, especially investors. In the case under consideration, we assume that investors will have a two-year period of market exclusivity, after which the medical research team will lose its patent protection. This effectively means that other companies will be free to manufacture and sell the drug. The importance of formulating the right strategies to guarantee the company's profitability after that two-year period cannot, therefore, be overstated.
Reformulating the Drug for a New Patent
The removal of a patent holder's monopoly not only promotes but also encourages competition (Joly and Knoppers, 2014). There are several approaches the company could adopt to protect its market share and, in turn, guarantee its profitability going forward. To begin with, the company could develop a new version of the drug by making changes to the original compound. The new formulation would be presented as clinically superior to the older formulation (Gupta, Kumar, Roy, and Gaud, 2010). The company would then apply for a new patent and either re-launch the product as an improved version of the original or continue under the same brand dispensation.
In the words of Gupta, Kumar, Roy, and Gaud (2010), "developing and patenting new formulations that promote patent compliance … is particularly advantageous for defending against generics and protecting market share." While this approach can be very effective in protecting existing market share, it can also be costly. In addition to filing a new patent application, the company would be required to conduct new clinical trials. Furthermore, there remains a possibility that the new compound could still encounter significant competition from the original generic product (Joly and Knoppers, 2014).
References
Gupta, H., Kumar, S., Roy, S.K., & Gaud, R.S. (2010). Patent protection strategies. J Pharm Bioallied Sci, 2(1), 2–7.
Joly, Y., & Knoppers, B.M. (Eds.). (2014). Routledge handbook of medical law and ethics. New York, NY: Routledge.
Create your account
Always verify citation format against your institution’s current style guide requirements.